• 1
    Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 2011; 41: 139147.
  • 2
    Potters L, Klein EA, Kattan MW et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother. Oncol. 2004; 71: 2933.
  • 3
    Mendenhall WM, Nichols RC, Henderson R, Mendenhall NP. Is radical prostatectomy the “gold standard” for localized prostate cancer? Am. J. Clin. Oncol. 2010; 33: 511515.
  • 4
    Schostak M, Miller K, Schrader M. Radical prostatectomy in the 21st century – the gold standard for localized and locally advanced prostate cancer. Front. Radiat. Ther. Oncol. 2008; 41: 714.
  • 5
    Amling CL. Biochemical recurrence after localized treatment. Urol. Clin. North Am. 2006; 33: 147159.
  • 6
    Roberts WB, Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg. Oncol. 2009; 18: 268274.
  • 7
    Vlaev I, Chater N. Game relativity: how context influences strategic decision making. J. Exp. Psychol. Learn. Mem. Cogn. 2006; 32: 131149.
  • 8
    Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol. 2004; 5: 303313.
  • 9
    Lughezzani G, Briganti A, Karakiewicz PI et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur. Urol. 2010; 58: 687700.
  • 10
    Capitanio U, Briganti A, Gallina A et al. Predictive models before and after radical prostatectomy. Prostate 2010; 70: 13711378.
  • 11
    Karakiewicz PI, Hutterer GC. Predictive models and prostate cancer. Nat. Clin. Pract. Urol. 2008; 5: 8292.
  • 12
    Kotb AF, Elabbady AA. Prognostic factors for the development of biochemical recurrence after radical prostatectomy. Prostate Cancer 2011; doi: 10.1155/2011/485189.
  • 13
    Ross PL, Gerigk C, Gonen M et al. Comparisons of nomograms and urologists” predictions in prostate cancer. Semin. Urol. Oncol. 2002; 20: 8288.
  • 14
    Shariat SF, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? BJU Int. 2009; 103: 492495.
  • 15
    Cooper CS, Campbell C, Jhavar S. Mechanisms of disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. Nat. Clin. Pract. Urol. 2007; 4: 677687.
  • 16
    Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv. Anat. Pathol. 2008; 15: 319331.
  • 17
    Sørensen KD, Ørntoft TF. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev. Mol. Diagn. 2010; 10: 4964.
  • 18
    Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 2005; 12: 654659.
  • 19
    Walz J, Gallina A, Perrotte P et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007; 100: 12541258.
  • 20
    Kattan MW. When and how to use informatics tools in caring for urologic patients. Nat. Clin. Pract. Urol. 2005; 2: 183190.
  • 21
    Kattan MW. Should I use this nomogram? BJU Int. 2008; 102: 421422.
  • 22
    Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Validity of prognostic models: when is a model clinically useful? Semin. Urol. Oncol. 2002; 20: 96107.
  • 23
    Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113: 30753099.
  • 24
    Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 2006; 26: 565574.
  • 25
    Ficarra V, Sooriakumaran P, Novara G et al. Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification. Eur. Urol. 2012; 61: 541548.
  • 26
    Shikanov SA, Zorn KC, Zagaja GP, Shalhav AL. Trifecta outcomes after robotic-assisted laparoscopic prostatectomy. Urology 2009; 74: 619623.
  • 27
    Caire AA, Sun L, Lack BD et al. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer Prostatic Dis. 2010; 13: 248251.
  • 28
    Pinto F, Prayer-Galetti T, Gardiman M et al. Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol. Int. 2006; 76: 202208.
  • 29
    Pierorazio P, Desai M, McCann T, Benson M, McKiernan J. The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome. BJU Int. 2009; 103: 3842.
  • 30
    Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 2005; 173: 19381942.
  • 31
    Kumano M, Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Adverse prognostic impact of capsular incision at radical prostatectomy for Japanese men with clinically localized prostate cancer. Int. Urol. Nephrol. 2009; 41: 581586.
  • 32
    Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 14451451.
  • 33
    Steuber T, Graefen M, Haese A et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J. Urol. 2006; 175: 939944.
  • 34
    Gallina A, Chun FK, Briganti A et al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur. Urol. 2007; 52: 98105.
  • 35
    Ohori M, Kattan MW, Koh H et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J. Urol. 2004; 171: 18441849.
  • 36
    Koh H, Kattan MW, Scardino PT et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J. Urol. 2003; 170: 12031208.
  • 37
    Cagiannos I, Karakiewicz P, Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J. Urol. 2003; 170: 17981803.
  • 38
    Briganti A, Chun FK, Salonia A et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur. Urol. 2006; 49: 10191026.
  • 39
    Briganti A, Chun FK, Salonia A et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur. Urol. 2007; 51: 112119.
  • 40
    Baccala A Jr, Reuther AM, Bianco FJ Jr, Scardino PT, Kattan MW, Klein EA. Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multi-institutional study of 6740 patients. Urology 2007; 69: 536540.
  • 41
    Bhojani N, Ahyai S, Graefen M et al. Partin tables cannot accurately predict the pathological stage at radical prostatectomy. Eur. J. Surg. Oncol. 2009; 35: 123128.
  • 42
    Karakiewicz PI, Bhojani N, Capitanio U et al. External validation of the updated Partin tables in a cohort of North American men. J. Urol. 2008; 180: 898902.
  • 43
    Yu JB, Makarov DV, Sharma R, Peschel RE, Partin AW, Gross CP. Validation of the partin nomogram for prostate cancer in a national sample. J. Urol. 2010; 183: 105111.
  • 44
    Zorn KC, Gallina A, Hutterer GC et al. External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. J. Endourol. 2007; 21: 13451351.
  • 45
    Zorn KC, Capitanio U, Jeldres C et al. Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables. Int. J. Radiat. Oncol. Biol. Phys. 2009; 73: 14611467.
  • 46
    Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur. Urol. 2008; 53: 6880.
  • 47
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969974.
  • 48
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 1998; 90: 766771.
  • 49
    Kattan MW. Re: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin tables) based on cases from 2000 to 2005. Eur. Urol. 2007; 52: 1528.
  • 50
    Stephenson AJ, Scardino PT, Eastham JA et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl. Cancer Inst. 2006; 98: 715717.
  • 51
    May M, Knoll N, Siegsmund M et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J. Urol. 2007; 178: 19571962.
  • 52
    Lughezzani G, Budäus L, Isbarn H et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur. Urol. 2010; 57: 562568.
  • 53
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J. Clin. Oncol. 2003; 21: 21632172.
  • 54
    Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J. Natl. Cancer Inst. 2009; 101: 878887.
  • 55
    Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 2009; 27: 43004305.
  • 56
    D'Amico AV, Whittington R, Malkowicz SB et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J. Urol. 1998; 160: 20962101.
  • 57
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 1999; 17: 14991507.
  • 58
    Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 2005; 23: 70057012.
  • 59
    Walz J, Chun FK, Klein EA et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J. Urol. 2009; 181: 601607.
  • 60
    Suardi N, Porter CR, Reuther AM et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008; 112: 12541263.
  • 61
    Porter CR, Suardi N, Kodama K et al. A nomogram predicting metastatic progression after radical prostatectomy. Int. J. Urol. 2008; 15: 889894.
  • 62
    Dotan ZA, Bianco FJ Jr, Rabbani F et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J. Clin. Oncol. 2005; 23: 19621968.
  • 63
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15911597.
  • 64
    Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin. Cancer Res. 2005; 11: 86698673.
  • 65
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 2004; 351: 125135.
  • 66
    Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433439.
  • 67
    Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J. Clin. Oncol. 2005; 23: 69926998.
  • 68
    Stephenson AJ, Kattan MW, Eastham JA et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J. Clin. Oncol. 2006; 24: 39733978.
  • 69
    Cronin AM, Godoy G, Vickers AJ. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J. Urol. 2010; 183: 984989.
  • 70
    Kattan MW, Vickers AJ, Yu C et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009; 115: 10051010.
  • 71
    Eastham JA, Kattan MW, Riedel E et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J. Urol. 2003; 170: 22922295.
  • 72
    Bleeker SE, Moll HA, Steyerberg EW et al. External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 2003; 56: 826832.
  • 73
    Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J. Clin. Epidemiol. 2003; 56: 441447.
  • 74
    Chun FK-H, Steuber T, Erbersdobler A et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur. Urol. 2006; 49: 820826.
  • 75
    Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J. Androl. 2009; 11: 5767.
  • 76
    Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl. Cancer Inst. 2002; 94: 981990.
  • 77
    Schröder FH. Review of diagnostic markers for prostate cancer. Recent Results Cancer Res. 2009; 181: 173182.
  • 78
    Charrier JP, Tournel C, Michel S et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 2001; 22: 18611866.
  • 79
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J. Urol. 2002; 167: 103111.
  • 80
    Djavan B, Eckersberger E, Finkelstein J, Sadri H, Taneja SS, Lepor H. Prostate-specific antigen testing and prostate cancer screening. Prim. Care 2010; 37: 441459.
  • 81
    Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007; 249: 3039.
  • 82
    Southwick PC, Catalona WJ, Partin AW et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J. Urol. 1999; 162: 13461351.
  • 83
    Graefen M, Karakiewicz PI, Cagiannos I et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 2002; 167: 13061309.
  • 84
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur. Urol. 2009; 55: 563574.
  • 85
    Steuber T, Vickers AJ, Haese A et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int. J. Cancer 2006; 118: 12341240.
  • 86
    Whitman EJ, Groskopf J, Ali A et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 2008; 180: 19751978.
  • 87
    Karnak D, Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr. Drug Targets 2010; 11: 699707.
  • 88
    Oxley JD, Winkler MH, Parry K, Brewster S, Abbott C, Gillatt DA. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int. 2002; 89: 2732.
  • 89
    Pollack A, Cowen D, Troncoso P et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003; 97: 16301638.
  • 90
    July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179188.
  • 91
    Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology 2010; 75: 454459.
  • 92
    Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86103.
  • 93
    Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anticancer Res. 2006; 26: 15831587.
  • 94
    Henshall SM, Quinn DI, Lee CS et al. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res. 2001; 7: 544550.
  • 95
    Cordon-Cardo C, Koff A, Drobnjak M et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 1998; 90: 12841291.
  • 96
    Freedland SJ, deGregorio F, Sacoolidge JC et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J. Urol. 2003; 169: 13251330.
  • 97
    Rigaud J, Tiguert R, Decobert M et al. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate 2004; 58: 269276.
  • 98
    Furukawa J, Miyake H, Takenaka A, Hara I, Fujisawa M. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. BJU Int. 2007; 100: 310314.
  • 99
    Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol. 2010; 28: 145151.
  • 100
    McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br. J. Cancer 2008; 98: 10941101.
  • 101
    Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007; 67: 614622.
  • 102
    Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 2007; 13: 70037011.
  • 103
    Strohmeyer D, Rössing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42: 2633.
  • 104
    Shariat SF, Andrews B, Kattan MM, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 10081015.
  • 105
    Kattan MW, Shariat SF, Andrews B et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol. 2003; 21: 35733579.
  • 106
    Gohji K, Fujimoto N, Hara I et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 1998; 79: 96101.
  • 107
    Shariat SF, Park S, Trinh QD, Roehrborn CG, Slawin KM, Karakiewicz PI. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. J. Urol. 2007; 178: 12291236.
  • 108
    Haese A, Graefen M, Huland H, Lilja H. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. Curr. Urol. Rep. 2004; 5: 231240.
  • 109
    Lopergolo A, Zaffaroni N. Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009; 115: 30583067.
  • 110
    So A, Hadaschik B, Sowery R, Gleave M. The role of stress proteins in prostate cancer. Curr. Genomics 2007; 8: 252261.
  • 111
    Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int. J. Urol. 2005; 12: 785794.
  • 112
    Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother. Pharmacol. 2005; 56: 4757.
  • 113
    Pins MR, Fiadjoe JE, Korley F et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis. 2004; 7: 243248.
  • 114
    Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol. Rep. 2005; 14: 13711375.
  • 115
    Miyake H, Muramaki M, Kurahashi T et al. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 2006; 68: 609614.
  • 116
    de Cárcer G, Pérez de Castro I, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr. Med. Chem. 2007; 14: 969985.
  • 117
    Ellinger J, Haan K, Heukamp LC et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008; 68: 4249.
  • 118
    Stephenson AJ, Smith A, Kattan MW et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005; 104: 290298.